New hope for Tough-to-Treat uterine cancer
NCT ID NCT05542407
Summary
This early-stage study is testing the safety of combining two drugs, atezolizumab and ONC201, for women with advanced or returning endometrial cancer that has spread. The trial will enroll 58 participants, including both obese and non-obese patients, to find the best dose for future testing. The goal is to see if this new combination can help control a cancer where current treatments often fail.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.